EVO - CONSENSUS CO - Evotec SE

Evotec SE (EVO) relies on external cloud computing for processing genomic arrays and partner-managed hardware services. The company is implementing automated biomolecule screening systems, which accelerate preclinical stages. Growth potential is based on the transition to AI-driven molecular modeling instead of manual testing, with the indicator standing at 2.76. The current stock quotes visualized below demonstrate the market dynamics of this asset.

The consensus forecast reflects the arithmetic mean of target prices from leading analysts to determine fundamental growth potential. The average fair value estimate for Evotec SE (EVO) on GURU.Markets visualizes the gap between the current price and the calculated business equivalent. An excessively narrow spread signals that the asset is overbought and faces a risk of stagnation. For Evotec SE (EVO), this indicator depends critically on the volume of partners' R&D budgets. The valuation trend confirms market confidence in the efficiency of bio-platforms and future milestone payments.